Harmony Biosciences Holdings, Inc. 10-Q Summary
Business context and reporting period
Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases. Its principal product is WAKIX (pitolisant), approved in the United States for excessive daytime sleepiness and cataplexy in adults with narcolepsy. The filing covers the quarter and nine months ended September 30, 2023; financial statements are unaudited and presented under U.S. GAAP.
WAKIX remained the primary source of revenue. Average patients on WAKIX were approximately 5,800 during the quarter, and the company reported formulary access covering more than 80% of insured U.S. lives.
Financial performance and key metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Net product revenue | $160.3 million | $117.2 million | $413.6 million | $309.5 million |
| Gross profit | $128.0 million | $94.2 million | $335.5 million | $253.0 million |
| Gross margin | 79.8% | 80.4% | 81.1% | 81.7% |
| Operating income | $64.5 million | $11.9 million | $151.8 million | $72.6 million |
| Operating margin | 40.2% | 10.2% | 36.7% | 23.4% |
| Net income | $38.5 million | $87.9 million | $102.2 million | $133.0 million |
| Diluted EPS | $0.63 | $1.44 | $1.68 | $2.18 |
| Net cash from operating activities | Not separately provided | Not separately provided | $142.7 million | $117.8 million |
Revenue increased 36.7% in the quarter and 33.6% for the nine-month period, driven by higher WAKIX unit shipments and the net effect of a 7.0% price increase implemented in January 2023. Unit shipments increased 28.2% in the quarter and 26.9% year to date.
Cost of product sales increased faster than revenue, reaching 20.2% of revenue in the quarter and 18.9% year to date, compared with 19.6% and 18.3%, respectively, in the prior-year periods. Management attributed the increase primarily to higher royalties and entering a higher royalty tier earlier in 2023.
Research and development expense declined to $17.5 million in the quarter and $45.8 million year to date, primarily because the prior-year periods included a $30.0 million Bioprojet licensing fee. Sales and marketing expense increased to $23.4 million in the quarter and $70.5 million year to date, reflecting expanded sales personnel and patient engagement activities. General and administrative expense increased to $22.5 million in the quarter and $67.4 million year to date.
Net income declined despite higher operating income because Q3 2022 and nine-month 2022 results benefited from income tax benefits of $80.0 million and $72.4 million, respectively, related primarily to releasing a deferred-tax-asset valuation allowance. The 2023 effective tax rates were 25.8% for the quarter and 23.5% year to date.
Liquidity, cash flow, debt, and capital allocation
- Cash, cash equivalents, and investments totaled approximately $438.4 million at September 30, 2023; cash, cash equivalents, and restricted cash totaled $324.9 million.
- Operating cash flow was $142.7 million for the first nine months, compared with $117.8 million in the prior-year period.
- Investing cash flow was negative $10.4 million, primarily reflecting purchases of investment securities substantially offset by maturities and sales.
- Financing cash flow was negative $52.0 million, including $50.0 million of share repurchases and debt refinancing-related payments.
- The company replaced the Blackstone Credit Agreement with $200.0 million of senior secured term loans under a new JPMorgan-led facility. Net carrying value of debt was $197.1 million at September 30, 2023.
- The new term loans mature on July 26, 2028, bear interest at either a base rate plus 2.50% to 3.00% or Term SOFR plus 0.10% and 3.50% to 4.00%, and require quarterly principal payments beginning December 31, 2023. The company reported compliance with all debt covenants.
- The company repurchased and retired 1,439,792 shares for $50.0 million under the August 2023 program, leaving $75.0 million authorized at quarter-end.
Material changes versus the prior comparable period
- Revenue and operating income grew substantially because of higher WAKIX volume and pricing, while prior-year operating expenses included a $30.0 million licensing fee.
- Gross margin declined modestly because of higher royalty tiers.
- Operating cash generation improved, but net income and EPS declined because the prior year included significant tax benefits.
- The company refinanced and increased its reported principal debt to $200.0 million, recognizing a $9.8 million loss on extinguishment of the Blackstone debt.
- Share count decreased by approximately 1.0 million shares from December 31, 2022, primarily because of the share repurchase program.
Guidance, outlook, commentary, risks, and unusual items
The filing does not provide clear numerical revenue, earnings, or cash-flow guidance. Management expects WAKIX sales to increase over time and expects sales and marketing, general and administrative, and research and development expenses to remain significant or increase as commercialization and pipeline activities expand.
- Management believes available cash, investments, and anticipated operating cash generation will fund operational and planned investing needs for at least the next twelve months.
- Management expects adequate WAKIX supply into the first quarter of 2025, with additional active pharmaceutical ingredient inventory expected to support at least 36 months beyond that period.
- The Phase 3 INTUNE study in idiopathic hypersomnia completed enrollment in May 2023. After quarter-end, the company reported that the primary endpoint did not achieve statistical significance, although management cited favorable trends and stated that it was evaluating next steps with the FDA.
- The company expects to initiate the Phase 3 TEMPO study in Prader-Willi syndrome in the first quarter of 2024 and expected topline results from its myotonic dystrophy study in the fourth quarter of 2023.
- After quarter-end, on October 10, 2023, the company acquired Zynerba Pharmaceuticals for $60.0 million in cash plus contingent value rights tied to clinical, regulatory, and sales milestones. The acquisition was funded with cash on hand.
- On October 27, 2023, the company terminated the August repurchase program and authorized a new program for up to $200.0 million of repurchases.
- Key risks include dependence on WAKIX, three specialty-pharmacy customers representing all gross accounts receivable and nine-month product revenue, single-source suppliers for each product and active pharmaceutical ingredient, reimbursement and market-acceptance risks, regulatory and clinical-trial uncertainty, competition, intellectual-property protection, and variable interest rates.
- Additional potential obligations include up to $155.0 million of future development and sales milestones under the 2022 Bioprojet agreement and milestone payments under the HBS-102 asset purchase agreement.
Most important facts for investors to verify
- Whether WAKIX prescription volume and pricing can sustain the reported revenue growth despite higher royalty rates and product costs.
- The full clinical and regulatory implications of the failed statistical primary endpoint in the INTUNE idiopathic hypersomnia study.
- The financial impact, integration progress, and milestone exposure associated with the Zynerba acquisition.
- The company’s ability to fund the new $200.0 million term-loan obligations, the July 2028 maturity payment, pipeline investment, and expanded share repurchases.
- Customer concentration, single-source manufacturing dependence, inventory shelf-life exposure, and the timing of any supply-chain diversification.
- Future tax rates and the extent to which the 2022 tax benefit distorts year-over-year net income comparisons.